Cover Image
市場調查報告書

Orbis Biosciences, Inc. :產品平台分析

Orbis Biosciences, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 351249
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Orbis Biosciences, Inc. :產品平台分析 Orbis Biosciences, Inc. - Product Pipeline Review - 2016
出版日期: 2016年04月20日 內容資訊: 英文 29 Pages
簡介

Orbis Biosciences, Inc. 是開發控制釋放的新藥物輸送系統的製藥公司,為了改善遵守與患者滿意度,致力於口服及可注入治療藥的藥物研發。該公司創造有活用與精密的粒子製造技術新的產品線,透過無前例的方法控制粒子參數改革目前產品系列。

本報告提供Orbis Biosciences, Inc.的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Orbis Biosciences, Inc.的基本資料

  • Orbis Biosciences, Inc.概要
  • 主要資訊
  • 企業資料

Orbis Biosciences, Inc.:R&D概要

  • 主要的治療範圍

Orbis Biosciences, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Orbis Biosciences, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式

Orbis Biosciences, Inc.:藥物簡介

  • prednisone
  • betamethasone valerate ER
  • bupivacaine extended release
  • etonogestrel ER
  • guaifenesin ER
  • meloxicam extended release
  • ORB-105
  • ORB-203
  • ritonavir
  • tramadol hydrochloride ER

Orbis Biosciences, Inc.:開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Orbis Biosciences, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08028CDB

Summary

Global Markets Direct's, 'Orbis Biosciences, Inc. - Product Pipeline Review - 2016', provides an overview of the Orbis Biosciences, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Orbis Biosciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Orbis Biosciences, Inc.
  • The report provides overview of Orbis Biosciences, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Orbis Biosciences, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Orbis Biosciences, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Orbis Biosciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Orbis Biosciences, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Orbis Biosciences, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Orbis Biosciences, Inc. Snapshot
    • Orbis Biosciences, Inc. Overview
    • Key Information
    • Key Facts
  • Orbis Biosciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Orbis Biosciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Orbis Biosciences, Inc. - Pipeline Products Glance
    • Orbis Biosciences, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Orbis Biosciences, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Orbis Biosciences, Inc. - Drug Profiles
    • prednisone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • betamethasone valerate ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bupivacaine hydrochloride ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etonogestrel ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • guaifenesin ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meloxicam ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ORB-105
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ORB-203
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ritonavir
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tramadol hydrochloride ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Orbis Biosciences, Inc. - Pipeline Analysis
  • Orbis Biosciences, Inc. - Pipeline Products by Target
  • Orbis Biosciences, Inc. - Pipeline Products by Route of Administration
  • Orbis Biosciences, Inc. - Pipeline Products by Molecule Type
  • Orbis Biosciences, Inc. - Pipeline Products by Mechanism of Action
  • Orbis Biosciences, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Orbis Biosciences, Inc., Key Information
  • Orbis Biosciences, Inc., Key Facts
  • Orbis Biosciences, Inc. - Pipeline by Indication, 2016
  • Orbis Biosciences, Inc. - Pipeline by Stage of Development, 2016
  • Orbis Biosciences, Inc. - Monotherapy Products in Pipeline, 2016
  • Orbis Biosciences, Inc. - Phase I, 2016
  • Orbis Biosciences, Inc. - Preclinical, 2016
  • Orbis Biosciences, Inc. - Pipeline by Target, 2016
  • Orbis Biosciences, Inc. - Pipeline by Route of Administration, 2016
  • Orbis Biosciences, Inc. - Pipeline by Molecule Type, 2016
  • Orbis Biosciences, Inc. - Pipeline Products by Mechanism of Action, 2016

List of Figures

  • Orbis Biosciences, Inc. - Pipeline by Top 10 Indication, 2016
  • Orbis Biosciences, Inc. - Pipeline by Stage of Development, 2016
  • Orbis Biosciences, Inc. - Monotherapy Products in Pipeline, 2016
  • Orbis Biosciences, Inc. - Pipeline by Top 10 Target, 2016
  • Orbis Biosciences, Inc. - Pipeline by Route of Administration, 2016
  • Orbis Biosciences, Inc. - Pipeline by Molecule Type, 2016
  • Orbis Biosciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top